Aushon Biosystems Introduces New Chief Scientific Officer

Aushon Biosystems Introduces New Chief Scientific Officer

BILLERICA, Mass.--(BUSINESS WIRE)-- Aushon BioSystems, Inc., a leading provider of advanced microarray products and laboratory services for biomarker discovery, development and analysis, announces that Sven Beushausen, Ph.D., has been appointed to the position of Chief Scientific Officer. Dr. Beushausen brings more than a quarter century of scientific research and product development experience to this new role, most recently as the Molecular Medicine Site Lead for Pfizer. Inc. He has served in a number of other senior-level scientific research positions throughout his career, including Senior Director and Global Lead, Proteomics and Reverse Pharmacology, and Director of the Toxicoproteomics Center of Emphasis in Drug Safety (Pfizer), as well as Director of Manufacturing Technologies (Invitrogen).

As Chief Scientific Officer, Dr. Beushausen will be responsible for driving Aushon's existing and future research and development programs through to successful market entry and adoption. He will also be relied on for creating and implementing the company's overall scientific strategy.

"We are thrilled to welcome Dr. Beushausen to Aushon at such an exciting time in our evolution," says Pete Honkanen, President and CEO of Aushon. "His experience in both basic and applied research, together with his ability to understand how our technology can be best utilized in a clinical research setting, will play a pivotal role in shaping our product positioning and platform development, as well as in helping to establish and implement our technical and corporate strategy moving forward. Furthermore, Dr. Beushausen's reputation as a thought leader will help us strengthen our growing relevance to both our customers and within the scientific community."

About Aushon BioSystems

Aushon BioSystems provides advanced microarray printing technology, robust biomarker content and innovative multiplex immunoassay development and detection services to leading pharmaceutical, biotechnology, academic and diagnostic organizations worldwide. Our unique multiplex immunoassay platform delivers exceptional performance, quality and reliability that accelerate pre-clinical and clinical biomarker research. Our customers trust us to provide the most reliable protein biomarker data available, which lowers costs and improves research productivity. For more information, please visit www.aushon.com.

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."